Lei Gao et al. [37] reported that minimal-dose decitabine maintenance combined with recombinant human granulocyte colony stimulating factor after allo-HSCT can reduce the relapse rate in high-risk AML patients undergoing allo-HSCT, with a 2-year relapse rate of 15.0% and 38.3% in the intervention and non-intervention groups, respectively. Here, CSF3 is linked to acute myeloid leukemia.